Clinical Trial Update: Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating daptomycin for infective endocarditis or bacteremia due to Staphylococcus aureus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Bacterial Endocarditis

Drugs mentioned

• Cubicin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Bacterial Endocarditis, Bacteremia | Phase 3 | Status: COMPLETED